



UNITED STATES PATENT AND TRADEMARK OFFICE

W
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/719,889	02/21/2001	Earl R. Owen	12724-002001	6045
7590	05/27/2004		EXAMINER	
Fish & Richardson Suite 500 4350 La Jolla Village Drive San Diego, CA 92122			CHISM, BILLY D	
			ART UNIT	PAPER NUMBER
			1654	

DATE MAILED: 05/27/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.	09/719,889	Applicant(s)	OWEN ET AL.
Examiner	B. Dell Chism	Art Unit	1654

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 18 March 2004.
2a) This action is FINAL. 2b) This action is non-final.
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-16, 19-22 and 24-65 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.
5) Claim(s) _____ is/are allowed.
6) Claim(s) 1-16, 19-22, 24-56, and 57-65 is/are rejected.
7) Claim(s) _____ is/are objected to.
8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
5) Notice of Informal Patent Application (PTO-152)
6) Other: _____

DETAILED ACTION

1. This office action is in response to Applicants' filing of a Request for Continued Examination on 18 March 2004. The finality of the last of office action dated 02 January 2004 is withdrawn and those rejections therein are resubmitted below as are rejections relating to any new or amended claims. Previously presented claims 1-16, 19-22 and 24-56, and newly added claims 57-65 are currently under consideration on the merits.
2. It is noted in Applicants' RCE that no arguments regarding the previously filed office action were filed and that those argument and/or comments are to be added upon receipt of this action.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
4. Claims 1, 27, 57-60 and 63 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The broad-brush discussion of making substances that serve as possible proteinaceous solders does not constitute a disclosure of a representative number of members of that class. No representative number of claimed solders was disclosed that would lend a full description to the entire class that is entailed by the instant claim 1. No other class members were shown to

Art Unit: 1654

possess the necessary physical properties required to perform as a constituent to a proteinaceous solder as claimed. The specification's general discussion of making proteinaceous solders constitutes an invitation to experiment by trial and error. Such does not constitute an adequate written description for the claimed substances. Putting the claimed methods into practice awaited someone actually discovering a necessary component of the invention. Without the substances called for in the methods, Applicant could no more be said to have possessed the complete claimed invention. While the specification identifies some broad categories of compounds that might work, these descriptions, without more precise guidelines, amount to little more than, "a starting point, a direction for further research." *Genentec, Inc. V. Novo Nordisk A/S*, 108 F.3d 1361, 1366, 42 U.S. PQ.2d (BNA) 1001, 1005 (Fed. Cir. 1997).

Furthermore, the courts have held that even though a specification is enabling for the practice of an entire class by one of skill in the art, the specification does not necessarily afford full written description of the entire class as claimed, . Application of DiLeone 436 F.2d 1404 (1971).

5. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claims 31 and 39 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, wherein the claims recite the indefinite phrase "or an analogue thereof." A protein analogue does not necessarily have to be a protein and since the solder requires a proteinaceous substance, there cannot be just an analogue thereof. Furthermore, it is unclear as what the metes and bounds of the limitation are regarding the analogues thereof.

Art Unit: 1654

7. Claims 2-10, 27-31, 40-44, 49-51, 54-55, 61-62 and 64-65 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. These claims are rejected for depending from rejected claims.

Claim Rejections - 35 USC § 102

8. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

9. Claims 1-7, 27-31, 43-44, 49, 57-63 are rejected under 35 U.S.C. 102(e) as being anticipated by Lauto *et al.* (U.S. Patent No. 6,323,037)(cited in previous office actions).

The examiner acknowledges Applicants' traversal of Lauto *et al.* in the previous office action, and the examiner acknowledges that Lauto *et al.* does not teach the denatured biomolecular solder as is explained in Applicants' response. However, the biomolecular solder of claim 1 and claim 57 that comprises a proteinaceous substance is not further limited by the incorporation of a method of making the biomolecular solder. Claim 1 and claim 57 are product-by-process claims, thus, the recitation of the method of making the biomolecular solder comprising a proteinaceous substance is not considered as a limitation to the product of claim 1 and claim 57. Without the method of making limitation in amended claim 1 and new claim 57, the claims only recite a biomolecular solder comprising a proteinaceous substance, which is taught by Lauto *et al.*

Art Unit: 1654

Subsequent dependent claims remain rejected for the reasons set forth in the previous office action. Lauto *et al.* teaches a biomolecular solder comprising a protein that can be albumin, with a dye comprising indocyanine green or methylene blue, with and adjuvant such as a growth factor, and wherein the solder is preformed.

Conclusion

No claims are allowed. Claims 11-16, 19-22, 24-26, 32-38, 45-48 and 52-53 are free of the prior art. Claims 1-7, 27-31, 43-44, 49, 57-63 are rejected as being anticipated by the prior art. Previously presented claims 1-16, 19-22 and 24-56, and newly added claims 57-65 are rejected.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to B. Dell Chism whose telephone number is 571-272-0962. The examiner can normally be reached on 7:30 AM - 4:30 PM, Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306 for regular communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

B. Dell Chism



CHRISTOPHER R. TATE
PRIMARY EXAMINER